The impact of visible tumor (PI-RADS >= 3) on upgrading and adverse pathology at radical prostatectomy in low risk prostate cancer patients: a biopsy core based analysis

Abstract

Deciding on the management of prostate cancer (PCa), especially GG1 PCa, is quite difficult. The most important thing that will help us in making active surveillance or definitive treatment decision is whether the tumor is a clinically significant tumor. To understand this, we discussed in this article that multiparametric MR, PI-RADS scoring and targeted biopsy can be used. Background